HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)

作者：Kikuchi Kiyoshi; Uchikado Hisaaki; Miura Naoki; Morimoto Yoko; Ito Takashi; Tancharoen Salunya; Miyata Kei; Sakamoto Rokudai; Kikuchi Chiemi; Iida Narumi; Shiomi Naoto; Kuramoto Terukazu; Miyagi Naohisa; Kawahara Ko Ichi^*

来源：Experimental and Therapeutic Medicine, 2011, 2(5): 767-770.

DOI：10.3892/etm.2011.310

• high mobility group box 1
• spinal cord injury
• transplantation

Historically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB I plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant patients. We hypothesize that inhibition of HMGB1 release rescues patients with SCI. Taken together, our findings suggest that anti-HMGB1 monoclonal antibodies or short hairpin RNA-mediated HMGB1 could be administered for spinal cord repair in SCI patients.

• 出版日期2011-10